ANGIOCRINE BIOSCIENCE INC has a total of 59 patent applications. It decreased the IP activity by 85.0%. Its first patent ever was published in 2015. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are FUND PUBLICA ANDALUZA PROGRESO Y SALUD, CYTOTHERAPEUTICS INC and NEUROTROPHINCELL PTY LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Australia | 7 | |
#4 | Canada | 7 | |
#5 | China | 7 | |
#6 | Republic of Korea | 6 | |
#7 | United States | 6 | |
#8 | Hong Kong | 3 | |
#9 | Singapore | 3 | |
#10 | Israel | 2 | |
#11 | Russian Federation | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Object sterilising | |
#6 | Microbiology | |
#7 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Nolan Daniel Joseph | 54 |
#2 | Davis Claude Geoffrey | 43 |
#3 | Ginsberg Michael Daniel | 41 |
#4 | Qiang Liang | 22 |
#5 | Finnegan Paul William | 18 |
#6 | Finnegal Paul William | 6 |
#7 | Nolan Daniel | 5 |
#8 | Zholudeva Lyandysha Viktorovna | 4 |
#9 | Lane Michael Aron | 4 |
#10 | Ginsberg Michael | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020243310A1 | Compositions and methods for thymic regeneration and t-cell reconstitution | |
CA3089324A1 | Compositions and methods for treatment of spinal cord injury | |
CN110121555A | Blood-brain barrier comprising being engineered endothelial cell | |
SG11201809049UA | Enhanced gene delivery methods | |
WO2017015245A1 | Methods and compositions for stem cell transplantation | |
KR20180053646A | Engineered endothelial cells expressing ETS transcription factors | |
CN107249607A | Biocompatible implant including being engineered endothelial cell | |
US2017137781A1 | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |